Literature DB >> 1465616

Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.

H Mizoguchi1, J J O'Shea, D L Longo, C M Loeffler, D W McVicar, A C Ochoa.   

Abstract

Impaired immune responses occur frequently in cancer patients or in tumor-bearing mice, but the mechanisms of the tumor-induced immune defects remain poorly understood. In an in vivo murine colon carcinoma model (MCA-38), animals bearing a tumor longer than 26 days develop CD8+ T cells with impaired cytotoxic function, decreased expression of the tumor necrosis factor-alpha and granzyme B genes, and decreased ability to mediate an antitumor response in vivo. T lymphocytes from tumor-bearing mice expressed T cell antigen receptors that contained low amounts of CD3 gamma and completely lacked CD3 zeta, which was replaced by the Fc epsilon gamma-chain. Expression of the tyrosine kinases p56lck and p59fyn was also reduced. These changes could be the basis of immune defects in tumor-bearing hosts.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1465616     DOI: 10.1126/science.1465616

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  147 in total

1.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.

Authors:  M C Gong; J B Latouche; A Krause; W D Heston; N H Bander; M Sadelain
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage.

Authors:  V P Dave; Z Cao; C Browne; B Alarcon; G Fernandez-Miguel; J Lafaille; A de la Hera; S Tonegawa; D J Kappes
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

4.  Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis.

Authors:  E Matutes; E Coelho; M J Aguado; R Morilla; A Crawford; K Owusu-Ankomah; D Catovsky
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

Review 5.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

6.  Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; Yong F Li; Xiaoqiang Kang; Rejean Lapointe; Patrick Hwu; Steven A Rosenberg; Nicholas P Restifo
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

7.  Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence.

Authors:  M R Young; J Ihm; Y Lozano; M A Wright; M M Prechel
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

8.  Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.

Authors:  T Gedde-Dahl; E Nilsen; E Thorsby; G Gaudernack
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

Review 10.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.